首页> 美国卫生研究院文献>Journal of Clinical Medicine >Venous Thromboembolism among Hospitalized Patients with COVID-19 Undergoing Thromboprophylaxis: A Systematic Review and Meta-Analysis
【2h】

Venous Thromboembolism among Hospitalized Patients with COVID-19 Undergoing Thromboprophylaxis: A Systematic Review and Meta-Analysis

机译:住院治疗患者的静脉血栓栓塞患者血栓血管抑制性血栓性血栓性患者:系统评价和荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: Preliminary evidence indicates that prophylactic-dose thromboprophylaxis may be inadequate to control the increased risk of venous thromboembolism (VTE) in patients hospitalized for coronavirus disease 2019 (COVID-19) infection. Additionally, it remains unclear whether the D-dimer measurement is useful for VTE risk stratification among COVID-19 patients. This study aimed to offer benchmark data on the incidence of VTE and to examine the difference in D-dimer levels among anticoagulated COVID-19 patients with and without VTE incident. Methods: A comprehensive literature review of PubMed from inception to May 2020 was performed for original studies that reported the frequency of VTE and death among COVID-19 patients who received thromboprophylaxis on hospitalization. The endpoints included VTE (a composite of pulmonary embolism (PE) or deep vein thrombosis (DVT)), PE, DVT, and mortality. Results: A total of 11 cohort studies were included. Among hospitalized COVID-19 patients, 23.9% (95% confidence interval (CI), 16.2% to 33.7%; I = 93%) developed VTE despite anticoagulation. PE and DVT were detected in 11.6% (95% CI, 7.5% to 17.5%; I = 92%) and 11.9% (95% CI, 6.3% to 21.3%; I = 93%) of patients, respectively. Patients in the intensive care unit (ICU) had a higher risk for VTE (30.4% )95% CI, 19.6% to 43.9%)) than those in the ward (13.0% (95% CI, 5.9% to 26.3%)). The mortality was estimated at 21.3% (95% CI, 17.0% to 26.4%; I = 53%). COVID-19 patients who developed VTE had higher D-dimer levels than those who did not develop VTE (mean difference, 2.05 µg/mL; 95% CI, 0.30 to 3.80 µg/mL; = 0.02). Conclusions: The heightened and heterogeneous risk of VTE in COVID-19 despite prophylactic anticoagulation calls into research on the pathogenesis of thromboembolic complications and strategy of thromboprophylaxis and risk stratification. Prominent elevation of D-dimer may be associated with VTE development and can be used to identify high-risk subsets.
机译:背景:初步证据表明预防剂 - 剂量血浆丙基丙基脲可能不足以控制在为冠状病毒疾病(Covid-19)感染的患者住院患者中静脉血栓栓塞(VTE)的风险增加。另外,仍然不清楚D-DIMOR测量是否可用于Covid-19患者之间的VTE风险分层。本研究旨在提供关于VTE的发生率的基准数据,并在没有VTE入射的情况下检查抗凝Covid-19患者的D-二聚体水平差异。方法:对2002月2020年5月的综合文献综述进行了从20025年5月进行的原创研究,报告了在住院治疗的Covid-19患者中VTE和死亡的频率。终点包括VTE(肺栓塞(PE)或深静脉血栓形成(DVT)),PE,DVT和死亡率。结果:共有11项队列研究。住院的Covid-19患者中,23.9%(95%置信区间(CI),16.2%至33.7%; I = 93%)尽管存在抗凝。在11.6%(95%CI,7.5%至17.5%的11.6%(95%至17.5%; I = 92%)和11.9%(95%CI,6.3%至21.3%; I = 93%)分别以11.6%(95%至17.5%; I = 93%)。重症监护病房(ICU)患者的VTE(30.4%)95%CI的风险较高,19.6%至43.9%)比病房(13.0%(95%CI,5.9%至26.3%))) 。死亡率估计为21.3%(95%CI,17.0%至26.4%; i = 53%)。开发VTE的Covid-19患者具有比未发育VTE的D二聚体水平更高(平均差异,2.05μg/ ml; 95%CI,0.30至3.80μg/ ml; = 0.02)。结论:Covid-19中VTE中VTE的高度和异质风险,尽管预防性抗凝治疗呼吁研究血栓栓塞并发症发病机制和血栓形成和风险分层策略。 D-Dimer的显着高度可能与VTE开发相关联,并且可用于识别高风险子集。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号